Morgan Stanley Maintains Overweight on Vir Biotechnology, Raises Price Target to $28

Benzinga · 6d ago
Morgan Stanley analyst Michelle Gilson maintains Vir Biotechnology (NASDAQ:VIR) with a Overweight and raises the price target from $25 to $28.